Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed advanced solid tumor
refractory to standard treatment or for which no effective standard therapy exists Bladder
cancer Breast cancer Colon cancer Esophageal cancer Gastric cancer Non-small cell lung
cancer Pancreatic cancer Evaluable or measurable disease B3 antigen present on more than
30% of tumor cells No prior or concurrent CNS metastasis Hormone receptor status: Not
specified

PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance
status: ECOG 0-1 Life expectancy: At least 3 months Hematopoietic: Granulocyte count
greater than 1,200/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin normal
SGOT/SGPT less than 5 times upper limit of normal Albumin at least 3.0 g/dL No history of
liver disease No positive hepatitis B or C antigen Renal: Creatinine no greater than 1.4
mg/dL Cardiovascular: No history of coronary artery disease No New York Association class
II-IV heart disease No arrhythmia requiring treatment No contraindications to pressor
therapy Pulmonary: FEV1 and FVC greater than 65% of predicted value Pulmonary function
test required of patients with significant smoking history or possible pulmonary disease
Other: No active peptic ulcer disease No known allergy to omeprazole No history of seizure
disorders No other concurrent malignancy No concurrent medical or psychiatric condition
that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients
must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks
since prior chemotherapy (6 weeks for mitomycin and nitrosourea) and recovered Endocrine
therapy: At least 3 weeks since prior hormonal therapy Radiotherapy: At least 3 weeks
since prior radiotherapy and recovered Surgery: Not specified